Literature DB >> 25595485

Endocannabinoid-mediated modulation of Gq/11 protein-coupled receptor signaling-induced vasoconstriction and hypertension.

Mária Szekeres1, György L Nádasy2, Gábor Turu1, Eszter Soltész-Katona1, Zoltán Benyó2, Stefan Offermanns3, Éva Ruisanchez2, Eszter Szabó4, Zoltán Takáts4, Sándor Bátkai5, Zsuzsanna E Tóth6, László Hunyady7.   

Abstract

Activation of G protein-coupled receptors (GPCRs) can induce vasoconstriction via calcium signal-mediated and Rho-dependent pathways. Earlier reports have shown that diacylglycerol produced during calcium signal generation can be converted to an endocannabinoid, 2-arachidonoylglycerol (2-AG). Our aim was to provide evidence that GPCR signaling-induced 2-AG production and activation of vascular type1 cannabinoid receptors (CB1R) is capable of reducing agonist-induced vasoconstriction and hypertension. Rat and mouse aortic rings were examined by myography. Vascular expression of CB1R was demonstrated with immunohistochemistry. Rat aortic vascular smooth muscle cells (VSMCs) were cultured for calcium measurements and 2-AG-determination. Inhibition or genetic loss of CB1Rs enhanced vasoconstriction induced by angiotensin II (AngII) or phenylephrine (Phe), but not by prostaglandin(PG)F2α. AngII-induced vasoconstriction was augmented by inhibition of diacylglycerol lipase (tetrahydrolipstatin) and was attenuated by inhibition of monoacylglycerol lipase (JZL184) suggesting a functionally relevant role for endogenously produced 2-AG. In Gαq/11-deficient mice vasoconstriction was absent to AngII or Phe, which activate Gq/11-coupled receptors, but was maintained in response to PGF2α. In VSMCs, AngII-stimulated 2-AG-formation was inhibited by tetrahydrolipstatin and potentiated by JZL184. CB1R inhibition increased the sustained phase of AngII-induced calcium signal. Pharmacological or genetic loss of CB1R function augmented AngII-induced blood pressure rise in mice. These data demonstrate that vasoconstrictor effect of GPCR agonists is attenuated via Gq/11-mediated vascular endocannabinoid formation. Agonist-induced endocannabinoid-mediated CB1R activation is a significant physiological modulator of vascular tone. Thus, the selective modulation of GPCR signaling-induced endocannabinoid release has a therapeutic potential in case of increased vascular tone and hypertension.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Angiotensin II; Blood pressure; Calcium signaling; Endocannabinoid; G protein-coupled receptor; Vasoconstriction

Mesh:

Substances:

Year:  2015        PMID: 25595485     DOI: 10.1016/j.mce.2015.01.012

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

Review 1.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

2.  The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo.

Authors:  Monte S Willis; Amro Ilaiwy; Megan D Montgomery; Paul C Simpson; Brian C Jensen
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

3.  Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators.

Authors:  Samantha E Yohn; Daniel J Foster; Dan P Covey; Mark S Moehle; Jordan Galbraith; Pedro M Garcia-Barrantes; Hyekyung P Cho; Michael Bubser; Anna L Blobaum; Max E Joffe; Joseph F Cheer; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Mol Psychiatry       Date:  2018-08-16       Impact factor: 15.992

4.  Oxyradical stress increases the biosynthesis of 2-arachidonoylglycerol: involvement of NADPH oxidase.

Authors:  Anberitha T Matthews; Jung Hwa Lee; Abdolsamad Borazjani; Lee C Mangum; Xiang Hou; Matthew K Ross
Journal:  Am J Physiol Cell Physiol       Date:  2016-10-26       Impact factor: 4.249

Review 5.  Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle.

Authors:  Basma Ghazi Eid
Journal:  J Microsc Ultrastruct       Date:  2018 Oct-Dec

6.  Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597.

Authors:  Marta Baranowska-Kuczko; Hanna Kozłowska; Monika Kloza; Ewa Harasim-Symbor; Michał Biernacki; Irena Kasacka; Barbara Malinowska
Journal:  Int J Mol Sci       Date:  2021-05-02       Impact factor: 5.923

Review 7.  Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox.

Authors:  Myriam Dao; Helene François
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

Review 8.  Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases.

Authors:  Dhanush Haspula; Michelle A Clark
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

9.  Cardiovascular phenotype of the Dmdmdx rat - a suitable animal model for Duchenne muscular dystrophy.

Authors:  Petra Lujza Szabó; Janine Ebner; Xaver Koenig; Ouafa Hamza; Simon Watzinger; Sandra Trojanek; Dietmar Abraham; Hannes Todt; Helmut Kubista; Klaus Schicker; Séverine Remy; Ignacio Anegon; Attila Kiss; Bruno K Podesser; Karlheinz Hilber
Journal:  Dis Model Mech       Date:  2021-02-22       Impact factor: 5.732

10.  Angiotensin II-Induced Cardiac Effects Are Modulated by Endocannabinoid-Mediated CB1 Receptor Activation.

Authors:  Zsuzsanna Miklós; Dina Wafa; György L Nádasy; Zsuzsanna E Tóth; Balázs Besztercei; Gabriella Dörnyei; Zsófia Laska; Zoltán Benyó; Tamás Ivanics; László Hunyady; Mária Szekeres
Journal:  Cells       Date:  2021-03-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.